{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:24:59Z","timestamp":1790277899661,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11910-018-0810-1","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T08:02:56Z","timestamp":1517472176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management"],"prefix":"10.1007","volume":"18","author":[{"given":"Christophoros","family":"Astaras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"de Micheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hundsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F.","family":"Hottinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"issue":"4","key":"810_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239 .","journal-title":"Nat Rev Cancer"},{"issue":"5256","key":"810_CR2","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136. https:\/\/doi.org\/10.1126\/science.271.5256.1734 .","journal-title":"Science"},{"issue":"19","key":"810_CR3","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293\u20137. https:\/\/doi.org\/10.1073\/pnas.192461099 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"810_CR4","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391. https:\/\/doi.org\/10.1172\/JCI80011 .","journal-title":"J Clin Invest"},{"issue":"6","key":"810_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806\u201312. https:\/\/doi.org\/10.1097\/WCO.0000000000000391 .","journal-title":"Curr Opin Neurol"},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"\u2022 Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.024 . A comprehensive retrospective analysis of adverse events related to inhibitors of the immune checkpoint PD-1.","journal-title":"Eur J Cancer"},{"key":"810_CR7","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Kao J C, Liao B, Markovic S N et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28873125 A well published series of 10 cases of neurologic adverse events of immune checkpoint inhibitors. The 2 cases of myositis are of particular interest.","DOI":"10.1001\/jamaneurol.2017.1912"},{"issue":"8","key":"810_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466 .","journal-title":"N Engl J Med"},{"issue":"26","key":"810_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1200690 .","journal-title":"N Engl J Med"},{"issue":"9","key":"810_CR10","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"JS Weber","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebb\u00e9 C, Hodi FS. MDX010-20 I. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675\u201382. https:\/\/doi.org\/10.1002\/cncr.27969 .","journal-title":"Cancer"},{"issue":"7","key":"810_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785\u201392. https:\/\/doi.org\/10.1200\/JCO.2015.66.1389 .","journal-title":"J Clin Oncol"},{"issue":"10","key":"810_CR12","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdx286 .","journal-title":"Ann Oncol"},{"issue":"2","key":"810_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(09)70334-1 .","journal-title":"Lancet Oncol"},{"issue":"10","key":"810_CR14","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330. https:\/\/doi.org\/10.1200\/JCO.2013.53.0105 .","journal-title":"J Clin Oncol"},{"issue":"8","key":"810_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"\u2022 Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de \u00c1vila ALR, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928\u201333. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1399 . The first report of 2 cases of immune checkpoint inhibitor encephalitis.","journal-title":"JAMA Neurol"},{"issue":"6","key":"810_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709\u201318. https:\/\/doi.org\/10.1634\/theoncologist.2016-0487 .","journal-title":"Oncologist"},{"key":"810_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001 .","journal-title":"Eur J Cancer"},{"issue":"19","key":"810_CR18","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1611299 .","journal-title":"N Engl J Med"},{"issue":"26","key":"810_CR19","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093 .","journal-title":"N Engl J Med"},{"issue":"10","key":"810_CR20","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385. https:\/\/doi.org\/10.1016\/S1470-2045(16)30364-3 .","journal-title":"Lancet Oncol"},{"issue":"20","key":"810_CR21","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937 .","journal-title":"N Engl J Med"},{"issue":"10031","key":"810_CR22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4 .","journal-title":"Lancet"},{"issue":"1","key":"810_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030 .","journal-title":"N Engl J Med"},{"issue":"1","key":"810_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1479-5876-9-204","volume":"9","author":"O Hamid","year":"2011","unstructured":"Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9(1):204. https:\/\/doi.org\/10.1186\/1479-5876-9-204 .","journal-title":"J Transl Med"},{"issue":"8","key":"810_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","volume":"30","author":"JC Yang","year":"2007","unstructured":"Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825\u201330. https:\/\/doi.org\/10.1097\/CJI.0b013e318156e47e .","journal-title":"J Immunother"},{"issue":"6","key":"810_CR26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/CMR.0b013e32834d3d88","volume":"21","author":"JS Weber","year":"2011","unstructured":"Weber JS, Amin A, Minor D, Siegel J, Berman D, O\u2019Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011;21(6):530\u20134. https:\/\/doi.org\/10.1097\/CMR.0b013e32834d3d88 .","journal-title":"Melanoma Res"},{"issue":"19","key":"810_CR27","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609 .","journal-title":"J Clin Oncol"},{"issue":"21","key":"810_CR28","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1501824 .","journal-title":"N Engl J Med"},{"issue":"10027","key":"810_CR29","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7 .","journal-title":"Lancet"},{"issue":"9948","key":"810_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(14)60958-2 .","journal-title":"Lancet"},{"issue":"suppl_4","key":"810_CR31","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"\u2022\u2022 Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdx225 . A comprehensive review of the guidelines for management of immune checkpoint inhibitor therapy by a comprehensive panel of experts.","journal-title":"Ann Oncol"},{"issue":"2","key":"810_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"\u2022\u2022 Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdw443 . A key paper that evaluates the possibility to treat patients with preexisting autoimmune conditions.","journal-title":"Ann Oncol"},{"issue":"2","key":"810_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28(2):377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdw558 .","journal-title":"Ann Oncol"},{"issue":"4","key":"810_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/CJI.0000000000000118","volume":"39","author":"LV Maul","year":"2016","unstructured":"Maul LV, Weichenthal M, K\u00e4hler KC, Hauschild A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother. 2016;39(4):188\u201390. https:\/\/doi.org\/10.1097\/CJI.0000000000000118 .","journal-title":"J Immunother"},{"issue":"2","key":"810_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4368 .","journal-title":"JAMA Oncol"},{"key":"810_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.038 .","journal-title":"Eur J Cancer"},{"key":"810_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2017.05.036","volume":"83","author":"W Boisseau","year":"2017","unstructured":"Boisseau W, Touat M, Berzero G, Savatovsky J, Marabelle A, Touitou V, et al. Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. Eur J Cancer. 2017;83:28\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.036 .","journal-title":"Eur J Cancer"},{"issue":"1","key":"810_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82\u201392. https:\/\/doi.org\/10.1007\/s11102-015-0671-4 .","journal-title":"Pituitary"},{"issue":"2","key":"810_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371\u201381. https:\/\/doi.org\/10.1530\/ERC-13-0499 .","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"810_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-12-0167","volume":"167","author":"A Juszczak","year":"2012","unstructured":"Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol. 2012;167(1):1\u20135. https:\/\/doi.org\/10.1530\/EJE-12-0167 .","journal-title":"Eur J Endocrinol"},{"issue":"230","key":"810_CR41","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. https:\/\/doi.org\/10.1126\/scitranslmed.3008002 .","journal-title":"Sci Transl Med"},{"key":"810_CR42","doi-asserted-by":"crossref","unstructured":"Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;2016.","DOI":"10.1136\/bcr-2016-215012"},{"issue":"1-2","key":"810_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jns.2014.06.023","volume":"344","author":"JJ Mandel","year":"2014","unstructured":"Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344(1-2):229\u201331. https:\/\/doi.org\/10.1016\/j.jns.2014.06.023 .","journal-title":"J Neurol Sci"},{"issue":"2","key":"810_CR44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000477162","volume":"10","author":"S Schneider","year":"2017","unstructured":"Schneider S, Potthast S, Komminoth P, Schwegler G, B\u00f6hm S. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017;10(2):473\u20138. https:\/\/doi.org\/10.1159\/000477162 .","journal-title":"Case Rep Oncol"},{"issue":"6","key":"810_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/MAJ.0000000000000584","volume":"350","author":"MK Stein","year":"2015","unstructured":"Stein MK, Summers BB, Wong CA, Box HL, Cleveland KO. Meningoencephalitis following Ipilimumab administration in metastatic melanoma. Am J Med Sci. 2015;350(6):512\u20133. https:\/\/doi.org\/10.1097\/MAJ.0000000000000584 .","journal-title":"Am J Med Sci"},{"issue":"7","key":"810_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.5692\/clinicalneurol.cn-000991","volume":"57","author":"F Konoeda","year":"2017","unstructured":"Konoeda F, Suzuki S, Nishimoto Y, Hoshino H, Takagi M. A case of myasthenia gravis and myositis induced by nivolumab. Rinsho Shinkeigaku. 2017;57(7):373\u20137. https:\/\/doi.org\/10.5692\/clinicalneurol.cn-000991 .","journal-title":"Rinsho Shinkeigaku"},{"issue":"12","key":"810_CR47","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","volume":"3","author":"C Maurice","year":"2015","unstructured":"Maurice C, Schneider R, Kiehl TR, Bavi P, Roehrl MHA, Mason WP, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015;3(12):1299\u2013302. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0141 .","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"810_CR48","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/ene.12249","volume":"20","author":"B Oyanguren","year":"2013","unstructured":"Oyanguren B, S\u00e1nchez V, Gonz\u00e1lez FJ, de Felipe A, Esteban L, L\u00f3pez-Send\u00f3n JL, et al. Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol. 2013;20(12):1566\u201370. https:\/\/doi.org\/10.1111\/ene.12249 .","journal-title":"Eur J Neurol"},{"issue":"3","key":"810_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","volume":"4","author":"L Khoja","year":"2016","unstructured":"Khoja L, Maurice C, Chappell M, MacMillan L, al-Habeeb AS, al-Faraidy N, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016;4(3):175\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0186 .","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"810_CR50","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","volume":"21","author":"EJ Gettings","year":"2015","unstructured":"Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler. 2015;21(5):670. https:\/\/doi.org\/10.1177\/1352458514549403 .","journal-title":"Mult Scler"},{"issue":"1","key":"810_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1078155215620922","volume":"23","author":"J LaPorte","year":"2017","unstructured":"LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin\u2019s lymphoma. J Oncol Pharm Pract. 2017;23(1):71\u20134. https:\/\/doi.org\/10.1177\/1078155215620922 .","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"810_CR52","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1200\/JCO.2011.38.7886","volume":"30","author":"M Maur","year":"2012","unstructured":"Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012;30(6):e76\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.38.7886 .","journal-title":"J Clin Oncol"},{"issue":"4","key":"810_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","volume":"13","author":"I Bot","year":"2013","unstructured":"Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278\u201380. https:\/\/doi.org\/10.1136\/practneurol-2012-000447 .","journal-title":"Pract Neurol"},{"issue":"2","key":"810_CR54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1684\/ejd.2016.2943","volume":"27","author":"K Oishi","year":"2017","unstructured":"Oishi K, Nakao M, Maeda S, Matsushita T, Ikeda T, Yamada T, et al. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. Eur J Dermatol. 2017;27(2):193\u20134. https:\/\/doi.org\/10.1684\/ejd.2016.2943 .","journal-title":"Eur J Dermatol"},{"issue":"1","key":"810_CR55","doi-asserted-by":"publisher","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745. https:\/\/doi.org\/10.1371\/journal.pone.0053745 .","journal-title":"PLoS One"},{"key":"810_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","volume":"45","author":"Y Gu","year":"2017","unstructured":"Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017;45:14\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2017.07.014 .","journal-title":"J Clin Neurosci"},{"issue":"2","key":"810_CR57","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/WNO.0000000000000217","volume":"35","author":"OL Yeh","year":"2015","unstructured":"Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol. 2015;35(2):144\u20137. https:\/\/doi.org\/10.1097\/WNO.0000000000000217 .","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"810_CR58","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0194599815606701","volume":"153","author":"AL Altman","year":"2015","unstructured":"Altman AL, Golub JS, Pensak ML, Samy RN. Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngol Head Neck Surg. 2015;153(5):894\u20135. https:\/\/doi.org\/10.1177\/0194599815606701 .","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"810_CR59","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s10637-011-9787-1","volume":"30","author":"F Bompaire","year":"2012","unstructured":"Bompaire F, Mateus C, Taillia H, de Greslan T, Lahutte M, Sallansonnet-Froment M, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30(6):2407\u201310. https:\/\/doi.org\/10.1007\/s10637-011-9787-1 .","journal-title":"Investig New Drugs"},{"issue":"3","key":"810_CR60","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/mus.23830","volume":"48","author":"G Manousakis","year":"2013","unstructured":"Manousakis G, Koch J, Sommerville RB, el-Dokla A, Harms MB, al-Lozi MT, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve. 2013;48(3):440\u20134. https:\/\/doi.org\/10.1002\/mus.23830 .","journal-title":"Muscle Nerve"},{"issue":"3","key":"810_CR61","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","volume":"375","author":"MF Maleissye de","year":"2016","unstructured":"de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375(3):296\u20137. https:\/\/doi.org\/10.1056\/NEJMc1515584 .","journal-title":"N Engl J Med"},{"issue":"4","key":"810_CR62","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/annonc\/mdr028","volume":"22","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991\u20133. https:\/\/doi.org\/10.1093\/annonc\/mdr028 .","journal-title":"Ann Oncol"},{"issue":"1","key":"810_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ. A severe case of ipilimumab-induced guillain-barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36(1):77\u20138. https:\/\/doi.org\/10.1097\/CJI.0b013e31827807dd .","journal-title":"J Immunother"},{"issue":"4","key":"810_CR64","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589\u201393. https:\/\/doi.org\/10.1093\/neuonc\/nou001 .","journal-title":"Neuro-Oncology"},{"issue":"9","key":"810_CR65","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jjco\/hyw090","volume":"46","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report. Jpn J Clin Oncol. 2016;46(9):875\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyw090 .","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"810_CR66","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","volume":"54","author":"KH Lau","year":"2016","unstructured":"Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54(1):157\u201361. https:\/\/doi.org\/10.1002\/mus.25141 .","journal-title":"Muscle Nerve"},{"issue":"3","key":"810_CR67","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25055","volume":"54","author":"J Zhu","year":"2016","unstructured":"Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016;54(3):506\u20137. https:\/\/doi.org\/10.1002\/mus.25055 .","journal-title":"Muscle Nerve"},{"key":"810_CR68","doi-asserted-by":"crossref","first-page":"232470961667431","DOI":"10.1177\/2324709616674316","volume":"4","author":"SD Phadke","year":"2016","unstructured":"Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep. 2016;4:2324709616674316.","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"1","key":"810_CR69","first-page":"119","volume":"78","author":"O Maeda","year":"2016","unstructured":"Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78(1):119\u201322.","journal-title":"Nagoya J Med Sci"},{"issue":"11","key":"810_CR70","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127\u201334. https:\/\/doi.org\/10.1212\/WNL.0000000000004359 .","journal-title":"Neurology"},{"issue":"33","key":"810_CR71","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","volume":"33","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Saranga-Perry V, Lavin PJ, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33(33):e122\u20134. https:\/\/doi.org\/10.1200\/JCO.2013.51.1683 .","journal-title":"J Clin Oncol"},{"issue":"2","key":"810_CR72","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.24648","volume":"52","author":"AI Loochtan","year":"2015","unstructured":"Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52(2):307\u20138. https:\/\/doi.org\/10.1002\/mus.24648 .","journal-title":"Muscle Nerve"},{"key":"810_CR73","doi-asserted-by":"crossref","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2017; 1078155216687389.","DOI":"10.1177\/1078155216687389"},{"issue":"27","key":"810_CR74","doi-asserted-by":"publisher","first-page":"e7350","DOI":"10.1097\/MD.0000000000007350","volume":"96","author":"YH Chen","year":"2017","unstructured":"Chen YH, Liu FC, Hsu CH, Chian CF. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine (Baltimore). 2017;96(27):e7350. https:\/\/doi.org\/10.1097\/MD.0000000000007350 .","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"810_CR75","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","volume":"27","author":"NL Gonzalez","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A, Marks SM, \u017divkovi\u0107 SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27(3):266\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.002 .","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"810_CR76","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055\u20138. https:\/\/doi.org\/10.1111\/cas.12961 .","journal-title":"Cancer Sci"},{"key":"810_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128\u201336. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.041 .","journal-title":"Eur J Cancer"},{"issue":"2","key":"810_CR78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","volume":"27","author":"BH Nguyen","year":"2017","unstructured":"Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017;27(2):152\u20134. https:\/\/doi.org\/10.1097\/CMR.0000000000000310 .","journal-title":"Melanoma Res"},{"issue":"3","key":"810_CR79","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","volume":"40","author":"E Chang","year":"2017","unstructured":"Chang E, Sabichi AL, Sada YH. Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother. 2017;40(3):114\u20136. https:\/\/doi.org\/10.1097\/CJI.0000000000000161 .","journal-title":"J Immunother"},{"issue":"3","key":"810_CR80","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299\u2013308. https:\/\/doi.org\/10.1016\/S1470-2045(15)00544-6 .","journal-title":"Lancet Oncol"},{"issue":"6-7","key":"810_CR81","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","volume":"140","author":"M Lecouflet","year":"2013","unstructured":"Lecouflet M, Verschoore M, Giard C, Gohier P, le Corre Y, Milea D, et al. Orbital myositis associated with ipilimumab. Ann Dermatol Venereol. 2013;140(6-7):448\u201351. https:\/\/doi.org\/10.1016\/j.annder.2013.02.029 .","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"810_CR82","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","volume":"27","author":"H Vallet","year":"2016","unstructured":"Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016;27(7):1352\u20133. https:\/\/doi.org\/10.1093\/annonc\/mdw126 .","journal-title":"Ann Oncol"},{"issue":"1","key":"810_CR83","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","volume":"4","author":"MA Bilen","year":"2016","unstructured":"Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4(1):36. https:\/\/doi.org\/10.1186\/s40425-016-0139-8 .","journal-title":"J Immunother Cancer"},{"issue":"7","key":"810_CR84","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/CJI.0000000000000178","volume":"40","author":"A Pushkarevskaya","year":"2017","unstructured":"Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, Hassel JC. Severe ocular myositis after Ipilimumab treatment for melanoma: a report of 2 cases. J Immunother. 2017;40(7):282\u20135. https:\/\/doi.org\/10.1097\/CJI.0000000000000178 .","journal-title":"J Immunother"},{"issue":"12","key":"810_CR85","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1634\/theoncologist.2016-0170","volume":"21","author":"E Fox","year":"2016","unstructured":"Fox E, Dabrow M, Ochsner G. A case of nivolumab-induced myositis. Oncologist. 2016;21(12):e3. https:\/\/doi.org\/10.1634\/theoncologist.2016-0170 .","journal-title":"Oncologist"},{"issue":"8","key":"810_CR86","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1080\/10428194.2016.1265115","volume":"58","author":"L Saini","year":"2017","unstructured":"Saini L, Chua N. Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine. Leuk Lymphoma. 2017;58(8):2011\u20133. https:\/\/doi.org\/10.1080\/10428194.2016.1265115 .","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"810_CR87","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/annonc\/mdw655","volume":"28","author":"CL Haddox","year":"2017","unstructured":"Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol. 2017;28(3):673\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdw655 .","journal-title":"Ann Oncol"},{"issue":"21","key":"810_CR88","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.41.6750 .","journal-title":"J Clin Oncol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-018-0810-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T03:34:27Z","timestamp":1570678467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-018-0810-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s11910-018-0810-1","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"1 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Christophoros Astaras, Rita de Micheli, and Bianca Moura declare no conflict of interest.Andreas F. Hottinger reports grants from Novocure and Astellas, paid to his institution.Thomas Hundsberger has received paid travel compensation from BMS Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"3"}}